RDD Pharma, a New York and Tel Aviv, Israel-based developer of treatments for lower gastro-intestinal disorders, raised $9.5M in Series B funding.
Backers included new investors Pharmascience and an international life science fund, as well as existing investors OrbiMed and Capital Point.
The company intends to use the funds to advance programs globally in anal fissure, fecal incontinence, radiation colitis/proctitis and pruritus ani.
Led by CEO Jason Laufer, RDD Pharma is a specialty pharma company focused on fast-track development and commercialization of innovative therapeutics for anorectal diseases and lower-gastrointestinal tract disorders. The company has two clinical stage products which serve significant unmet needs: RDD-1219 for chronic anal fissure, currently enrolling patients in a multicenter European Phase 3 study, with 300 patients already enrolled and RDD-0315 for fecal incontinence, an indication for which there are no approved Rx products. Two pre-clinical assets are also in development for pruritis ani and radiation colitis/proctitis.